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Abstract
In recent years, the incidence of lung cancer (LC) has been increasing throughout the 
world and is the most common type of cancer in all regions of the world, occurring more 
frequently in men than in women. Paraneoplastic syndromes (PNS) refer to clinical 
conditions that develop in relation to tumors, without physical effects of the primary or 
metastatic tumors. The development of PNS is not associated with the size of the primary 
tumor or the extent of metastases. It is usually seen in small-cell lung cancer (SCLC) 
as well as other types of lung cancer. PNS developed in almost 1 in 10 patients with 
lung cancer and it may be an indicator for the diagnosis of lung cancer and it can be 
seen during later stages of cancer or at the time of cancer recurrence. Accordingly, the 
identification of these syndromes can be helpful in the early diagnosis of occult cancers, 
allowing timely treatment. PNS decreases the quality of life of the patients with cancer 
and thus requires specific treatment. Moreover, these conditions can be used as a marker 
of cancer activity and can predict prognosis. In this section, a detailed description of PNS 
is provided.
Keywords: lung cancer, small-cell lung cancer, non-small-cell lung cancer, 
paraneoplastic syndromes
1. Introduction
1.1. Definition
The term “paraneoplastic syndrome (PNS)” refers to tumor-related symptoms and findings 
that are independent of the direct, local extent or physical effects of metastases. PNS develops 
in response to the effects of hormones and cytokines released from cancer cells, or due to 
the immunologic response of cancer cells [1, 2]. In this regard, there is no single mechanism 
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underlying the development of PNS, and potential mechanisms have not yet been clearly 
understood. On the other hand, several tumor-secreted proteins that may be associated with 
the development of PNS have been defined in the recent years. Generally, the ectopic produc-
tion of peptide hormones with hormonal activity and immunological mechanisms can be seen 
in patients with PNS.
The diagnosis and treatment of PNS are complementary parts of lung cancer (LC) manage-
ment. PNS may involve several organs and systems, and so may therefore result in neurologi-
cal, dermatological, hematological, nephrological, rheumatologic, metabolic, immunologic 
and constitutional signs and symptoms.
1.2. History
In 1865, Armand Trousseau, a French internal diseases specialist, stated that the identification 
of unexpected or migratory thrombophlebitis could indicate an occult visceral malignancy 
[3], and today, the development of superficial migratory thrombophlebitis related to visceral 
cancer is known as Trousseau syndrome. An Austrian dermatologist, Ferdinand von Hebra, 
underlined the significance of internal disease in the etiology of several skin manifestations 
such as urticaria, generalized pruritus, xanthoma, and pemphigus. In 1868, he further stated 
that skin pigmentation could be an indicator of cervical cancer [4, 5]. In 1890, a French physi-
cian named Auche defined peripheral nervous system involvement in patients with stomach, 
pancreas, and uterus cancer [6], while acanthosis nigricans associated with malignancy was 
reported separately by Pollitzer and Janovsky in 1890 [7]. Later, Brown identified the Cushing 
syndrome in a patient with small-cell lung cancer (SCLC) in 1928 [8], and in 1933, neuropathy 
development was reported in a patient with oat cell carcinoma (small-cell lung cancer) [9]. 
Guichard and Vignon used the term “paraneoplastic” for the first time in 1949 when they 
identified central and peripheral neuropathies in a patient with cervical cancer [10]. In 1957, 
Schwartz et al. reported hyponatremia in a patient with LC [11]. In 1967, Bartter and Schwartz 
defined the syndrome of inappropriate antidiuretic hormone secretion (SIADH) [12]. The 
relationship between the neurological PNS and LC was first suggested by Oppenheim at the 
end of the nineteenth century [9].
In the following years, etiologic and pathogenetic studies were carried out to evaluate the 
relationship between PNS and cancer including LC. Additionally, new PNS definitions and 
new developments have been made which are still ongoing.
1.3. Epidemiology
LC is currently the most common type of cancer throughout the world [13]. Due to the high 
incidence rate of LC and the relatively high frequency of PNS in SCLC cases, LC-related PNS 
is more common than other types of cancer [14–17]. However, it is difficult to estimate PNS 
frequency due to challenges in the identification of PNS and uncertainty in the differentia-
tion of its symptoms because of the underlying disease. PNS can be seen in all age groups 
of patients with cancer. However, due to the nature of cancer, it is more common in middle-
aged and older individuals. PNS develops in 1–7.4% of all patients with cancer, although it 
is estimated to develop in 20% of all patients with cancer [14]. The inclusion of generalized 
malignancy symptoms, such as cachexia and fever, increases PNS frequency up to 70% [18].
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PNS can occur both in patients with SCLC and with non-small-cell lung cancer (NSCLC). SCLC 
has a neuroendocrine origin and PNS is more common in such cancer types. PNS is seen by 
7–15% of all patients with LC. Systemic symptoms and findings of PNS develop in 50% of 
patients with SCLC and almost 10% of patients with NSCLC [19]. PNS develops secondary to LC 
and increases the severity of the disease. It is therefore crucial to recognize PNS in these patients.
Incidences of PNS will increase in the coming years thanks to the improvements in diagnosis 
and treatment of LC as well as in the diagnosis of PNS.
1.4. Pathophysiology
PNS may develop under the effects of substances released by the tumor or as a result of the 
cross-reactions between tissues and the antibodies produced against the tumor.
Studies investigating the pathogenesis of PNS offer some evidences that PNS develops based 
on different pathogenetic mechanisms, such as:
1. The production of special substances by tumor cells, leading specifically to the develop-
ment of PNS. These substances may be hormones, growth factors, vasoactive peptides, 
cytokines, enzymes or other signaling molecules.
2. Abnormal immune response of the host organ to the neo-antigens produced by the tumor 
or to other tumor products [7, 18, 20].
Endocrinologic PNS generally develops due to the increased production of hormones or 
hormone precursors by malignant cells. The best example for this is paraneoplastic Cushing 
syndrome seen in patients with SCLC [21].
Paraneoplastic hypercalcemia is an example of PNS associated with cytokine production. 
Some cytokines (IL-1, 3, and 6, prostaglandins, TGF-α, TNF-α [lymphotoxin], and TNF-β 
[cachectin], etc.) that are synthesized by the malignant cells may result in hypercalcemia by 
activating osteoclasts [22].
Cancer cells are recognized by the immune cells and lead to the production of antibodies. As 
cancer cells are identical to normal cells in nature, the antigens on the cancer cells are similar 
to those of natural cells. Therefore, the formed antibodies may have a cross-reaction with 
normal tissues. This pathophysiological condition is most commonly seen in neurological 
PNS [23, 24].
The main mechanism underlying above-described pathological response in patients with LC 
and other types of cancer still presents an unanswered question. The most appropriate answer 
to that would be inappropriate gene expression (IGE). IGE may be described as the formation 
of an inappropriate gene programmed to produce tumoral proteins in cancer cells. This may 
lead to the development of new disorders that will negatively affect patient well-being. Thus, 
the quality of life of the patient is impaired and the severity of the disease increases [18].
Genetic studies that will be performed in the future to identify IGEs in cancer patients will 
allow the early detection of PNS, even before the clinical diagnosis, and more importantly, 
will be helpful to identify malignant formations.
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2. Paraneoplastic syndromes
The diagnosis of PNS is relatively challenging, as lesions may develop in regions distant to the 
cancer and may not resemble a cancer-related disease, and the disorder has benign forms in 
general as well as malignant forms. PNS should be suspected in the presence of below char-
acteristics: absence of a defined etiology for the associated syndrome; correlation between the 
time of diagnosis of the syndrome and that of cancer; clinical and histological remission after 
complete surgical or chemotherapy treatment and a worsening of symptoms due to tumor 
residue [25].
Although PNS may be associated with a lot of malignancies, they are associated most com-
monly with lung cancer, specifically SCLC. Humoral hypercalcemia and SIADH, which 
is seen in orderly squamous cell and SCLC, are the most common PNSs. Multiple para-
neoplastic syndromes can be seen in patients with SCLC. In the literature, there have been 
patients with two or more paraneoplastic syndromes associated with SCLC, even though 
rarity. Paraneoplastic syndromes usually have a course parallel to the underlying malig-
nancy. Treating the underlying tumor is the first choice and symptomatic therapy can be 
useful [2, 26–29].
2.1. Classification
Paraneoplastic symptoms in LC can be seen almost in all systems, which can be listed as 
follows:
• Endocrine paraneoplastic syndromes
• Neurologic paraneoplastic syndromes
• Dermatologic paraneoplastic syndromes
• Rheumatologic paraneoplastic syndromes
• Nephrological paraneoplastic syndromes
• Hematologic paraneoplastic syndromes
• Others
2.2. Endocrine paraneoplastic syndromes
Endocrinological PNS generally develops due to excessive synthesis of hormones or hor-
mone precursors with low bioactivity, or the conversion of the precursors to more effective 
product(s) in the tumor tissue.
2.2.1. Ectopic Cushing syndrome
Secretion of ectopic adrenocorticotropic hormone (ACTH) from the tumor may result in Cushing 
syndrome, and high ACTH levels can be noted in almost 50% of patients with LC. Cushing 
syndrome may develop in 1–5% of patients with SCLC [30, 31], and of all the pulmonary 
Lung Cancer - Strategies for Diagnosis and Treatment26
neuroendocrine tumors, about 1–2% are accompanied by Cushing syndrome due to ectopic 
ACTH secretion, or the production of its precursor, proopiomelanocortin (POMC) [32].
Patients are typically admitted to clinics due to myopathy, centripetal obesity, facial plethora, 
hypertension, osteoporosis, hyperglycemia, hirsutism, and acne. The clinical symptoms have 
a rapid onset and are generally accompanied by hypokalemia and hyperglycemia.
Due to its rapid onset, patients generally are found to have electrolyte imbalances rather than 
having a cushingoid appearance, although typical cushingoid characteristics such as moon 
face and buffalo hump generally do not manifest, as hypercortisolism is an acute phenom-
enon and patients do not live long enough for the manifestation of morphological changes 
[33, 34].
Increased levels of free cortisol in the urine, elevated serum levels of ACTH or ACTH pre-
cursors, hypokalemia and hyperglycemia are helpful for the diagnosis of ectopic Cushing 
syndrome (ECS).
The prognosis of SCLC patients with Cushing syndrome is worse than in SCLC patients with-
out Cushing syndrome [35].
Treatment essentially involves treating the primary tumor. In the presence of non-resectable 
tumors, medications that inhibit steroid biosynthesis (metyrapone, ketoconazole) can be used 
for the treatment of ECS. Aminoglutethimide can be used to prevent androgenic side effects 
and octreotide may be helpful in reducing ACTH release. A bilateral adrenalectomy may also 
be considered [31].
2.2.2. Inappropriate antidiuretic hormone syndrome
Inappropriate antidiuretic hormone syndrome (IADHS) develops as a result of free water 
retention and increased extracellular fluid volume due to the irregular release of the antidi-
uretic hormone (ADH). This initiates a process characterized by a progressive dilution of 
plasma sodium and sodium loss through the kidneys.
It is generally seen in patients with SCLC, accounts for around 75% of all cancer-related 
IADHS. It is seen in 7–16% of patients with SCLC but may also occur in patients with NSCLC 
[36, 37].
Antidiuretic hormone (ADH) levels are generally elevated in LC patients with IADHS and in 
addition, patients may also have increased levels of atrial natriuretic peptide [38].
IADHS symptoms rarely manifest when plasma sodium levels are higher than 125 mEq/L. Plasma 
sodium levels below 125 mEq/L may result in symptoms such as weakness, tiredness, nausea, 
headache, lethargy, and confusion, while levels below 120 mEq/L may lead to seizure and 
coma [39].
Based on the definition of Bartter and Schwartz, a diagnosis of IADHS can be made in the 
presence of following findings:
• Serum Na < 134 mEq/l
• Plasma osmolality <275 mOsm/kg
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• Urine osmolality >500 mOsm/kg
• High urinary sodium concentration (>20mEq/l)
• Absence of clinical signs of volume depletion
• Presence of normal adrenal functions
• Presence of normal thyroid functions [1, 12]
• Presence of IADHS is a marker of poor prognosis [38]
If plasma sodium levels are higher than 130 mEq/L, fluid intake may be limited (500 mL/day) 
and/or patients may be given demeclocycline, which is a medication that blocks the response 
of renal tubules to ADH. A slow infusion of hypertonic saline solution and an IV furosemide 
infusion may be preferred in severe cases [31].
2.2.3. Hypercalcemia
Hypercalcemia develops in 6% of LC patients, and is most commonly seen in the presence 
of squamous cell carcinoma [40, 41]. In LC, hypercalcemia is caused by the production of 
parathyroid hormone-related protein (PTHrP) of the tumor and secretion of parathyroid 
hormone. Another mechanism leading to the development of hypercalcemia involves PTHrP 
increase as a result of granulocyte colony-stimulating factor signal. While increased 1.25(OH)
2
 
Vitamin D synthesis may result in hypercalcemia in some malignancies, this mechanism is not 
associated with hypercalcemia in LC [41].
Early symptoms of hypercalcemia include loss of appetite, nausea, vomiting, constipation, 
numbness, polyurea, polydypsia, and dehydration, while late symptoms include renal fail-
ure, nephrocalcinosis, confusion, and coma.
Elevated serum levels of ionized calcium, normal or decreased levels of parathyroid hormone 
and high PTHrP levels are diagnostic factors [9].
Treatment is essentially based on the treatment of the tumor-causing hypercalcemia. 
Symptomatic patients with high serum calcium levels should be treated with hydration and 
bisphosphonates, and any calcium supplements, thiazide diuretics, and lithium, all of which 
may alleviate hypercalcemia, should be discontinued [42].
2.2.4. Other endocrine paraneoplastic syndromes
In LC patients, hypoglycemia may occur due to ectopic insulin secretion and insulin-like 
growth factor (IGF) secretion.
Acromegaly may also occur as a result of ectopic growth hormone-releasing hormone 
(GHRH) or IGF secretion.
Moreover, carcinoid syndrome may develop in relation to the secretion of serotonin and simi-
lar vasoactive amines [41, 43].
Lung Cancer - Strategies for Diagnosis and Treatment28
2.3. Neurologic paraneoplastic syndromes
Neurologic PNS may develop by the involvement of central nervous system, peripheral 
nervous system or the neuromuscular junction and muscles. The majority of patients with 
neurologic PNS have SCLC (at a rate of 5%). In its pathogenesis, immune-system mediated 
reactions are seen in general. Immune cross-reactivity is seen between tumor cells and com-
ponents of the nervous system [9, 29, 44].
International criteria have been determined to facilitate the diagnosis of paraneoplastic neu-
rologic syndromes, defining “definite” and “possible” diagnoses. The definite diagnostic 
criteria are as follows:
• neurological symptoms that will develop cancer within 5 years and commonly accompany-
ing with cancer (limbic encephalitis, cerebellar degenerations, etc.);
• nonclassical neurologic syndrome that improves after cancer treatment without concomi-
tant immunotherapy;
• nonclassical neurologic syndrome with positive antibodies and a diagnosis of cancer 
within 5 years; and
• neurologic syndromes accompanied by “well-characterized” antibodies in the absence of a 
cancer diagnosis (anti-Hu, anti-CV2, anti-Ri, anti-Yo, anti-Tr, and anti-Ma2).
There are three categories of possible paraneoplastic neurologic syndrome diagnoses:
• presence of classical neurologic syndrome in the absence of cancer or antibodies, but a high 
risk of underlying tumor;
• presence of neurologic syndrome with non-classical antibodies in the absence of cancer; 
and
• presence of classical neurologic syndrome without antibodies or a malignancy [9, 45].
2.3.1. Encephalomyelitis
Paraneoplastic encephalomyelitis should be considered in the presence of neuronal loss and 
inflammation in multiple regions of the central nervous system, primarily in the hippocam-
pus (limbic encephalitis), Purkinje cells of the cerebellum (cerebellar degeneration), brainstem 
(brainstem encephalitis) and medulla spinalis (myelitis). Dorsal root-ganglion (sensorial neu-
ronopathy), as well as sympathetic and parasympathetic nerve and ganglions (orthostatic 
hypotension, gastrointestinal paresis, arrhythmia, erectile dysfunction) are known to be 
involved in the majority of the cases [46, 47].
It is thought to be developed with SCLC and due to the immune response that develops 
against the neural proteins expressed by the tumor. The most commonly identified antibody 
in paraneoplastic encephalomyelitis is the Hu (ANNA-1) antibody, although cases associated 
with CV2, amphiphysin, and Ri antibodies have also been reported.
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While it may start with relatively milder and focal signs such as epilepsia partialis continua, 
nonconvulsive epileptic status or frontal-type ataxia, the findings rapidly progress within 
weeks or months and may result in death in general. Neurological outcomes may not be sat-
isfying despite the treatment, as irreversible neuronal damage occurs in most of cases when 
the diagnosis is made. The worst neurological outcomes are seen in paraneoplastic encepha-
lomyelitis accompanied by Anti-Hu antibodies [48].
In addition to cancer treatment, immunomodulation plays a key role in the treatment of 
encephalomyelitis, and corticosteroids, steroid-sparing agents (azathioprine, cyclophospha-
mide, etc.), rituximab, IVIG, and plasmapheresis can be used for treatment [44].
2.3.2. Limbic encephalitis
Paraneoplastic limbic encephalitis manifests with major findings such as short-term memory 
loss, behavior/mood changes and epileptic seizures, and confusion, irritability, depression, 
sleep problems, hallucinations and psychosis in addition to major findings [49]. Moreover, 
hyperthermia and endocrine disorders may also develop due to hypothalamic dysfunction. 
Antibodies produced against the Hu, Ma2, CV2 and amphiphysin antigens expressed by 
the tumor have been identified in patients with paraneoplastic limbic encephalitis. For the 
diagnosis, demonstration of epileptic activity in the electroencephalographic examination, 
demonstration of temporal lobe involvement in magnetic resonance imaging (MR2), and an 
investigation of the cerebrospinal fluid (CSF) and auto-antibody test are required. The neuro-
logic response to treatment varies between patients with paraneoplastic limbic encephalitis, 
while 30–50% of patients may recover after the tumor treatment.
Just like in encephalomyelitis, immunomodulation plays a key role in treatment along with 
cancer-specific therapies, and corticosteroids, steroid-sparing agents (azathioprine, cyclo-
phosphamide, etc.), rituximab, IVIG, and plasmapheresis can be used for treatment [44].
2.3.3. Cerebellar degeneration
Paraneoplastic cerebellar degeneration is one of the most common PNS. Depending on 
the widespread cerebellar Purkinje cell death, it may have an acute or subacute onset and 
courses with a rapidly progressing pancerebellar syndrome. The antibodies associated 
with cerebellar degeneration include anti-Yo, Tr, Hu, Ma2, and Ri [50]. However, the most 
well-defined and frequently seen paraneoplastic cerebellar degeneration is associated with 
the Yo antibodies. Before developing findings of neurologic deficit, patients may experi-
ence flu-like prodromal signs and may then develop an ataxic gait, dysarthria, dyspha-
gia, diplopia, blurred vision, and transient opsoclonus. Patients initially have normal MR 
and CSF findings, however, inflammatory findings in CSF develop rapidly and an MR 
may demonstrate advanced cerebellar atrophy. Fast and effective treatment may prevent 
the progression of symptoms, but cerebellar degeneration is one of the most treatment-
resistant PNS.
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Like in limbic encephalitis, treatment may include the use of corticosteroids, steroid-sparing 
agents (azathioprine, cyclophosphamide, etc.), rituximab, IVIG, and plasmapheresis [44].
2.3.4. Lambert-Eaton myasthenic syndrome
Almost 60% of the Lambert-Eaton myasthenic syndrome (LEMS) cases have a paraneoplastic 
origin. SCLC is observed in the vast majority of cancer cases with LEMS, while other types of 
cancer are seen in a small number of cases [51]. LEMS develops in 3% of all SCLC cases, and 
LEMS develops as a result of the autoimmune response to the P/Q-type anti-voltage-gated 
calcium channels (VGCC) that exist on the pre-synaptic membrane of the neuromuscular 
junction, and 95% of the cases are found to be positive for this antibody. Of all cases with 
LEMS and SCLC, 64% are positive for SOX1 antibodies [41], and patients are generally admit-
ted with proximal muscle weakness, reduced or absent deep tendon reflexes, and findings 
of autonomic function impairment. Tumor treatment is known to be a key factor to predict 
the neurological outcomes. In cases with SCLC, treatment 3,4-diaminopyridine, a potassium 
channel antagonist, may provide significant recovery, and azathioprine and prednisolone 
may also be used for the treatment [41, 51, 52].
2.3.5. Opsoclonus-myoclonus
This syndrome is associated with involuntary chaotic conjugated rapid eye movements and 
myoclonic discharges in the head, neck, face, trunk, and legs as well as potential cerebellar 
ataxia. In some adult cases, anti-Ri, anti-Hu, anti-amphiphysin, and P/Q-type VGCC anti-
bodies may accompany cancer. Paraneoplastic opsoclonus and myoclonus respond well to 
treatment. Successful treatment can be achieved by the resection of the underlying tumor and 
elimination of circulating antibodies such as corticosteroids, intravenous immunoglobulin 
and plasmapheresis [41, 53].
2.3.6. Chronic gastrointestinal pseudo-obstruction
Chronic gastrointestinal pseudo-obstruction (CGP) is an autonomic neuropathy that is char-
acterized by gastrointestinal dysmotility without a mechanical obstruction, leading to symp-
toms of abdominal pain, nausea and constipation [41].
While CGP generally occurs in patients with SCLC, it may also be noted in patients with 
NSCLC. Anti-Hu antibodies are frequently positive. In addition to cancer treatment, agent 
such as octreotide, prednisone, and azathioprine can be used for the treatment of CGP [41, 54].
2.3.7. Others
Neurological PNS has a variety of clinical manifestations. Other than above-described syn-
dromes, patients may experience subacute sensory neuropathy involving the peripheral ner-
vous system, acute sensory-motor neuropathy (Guillain-Barre Syndrome, brachial neuritis), 
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neuropathy with vasculitis, myasthenia gravis involving the neuromuscular junction and 
muscles, acquired myotonia, and acute necrotizing myopathy [41].
2.4. Dermatologic paraneoplastic syndromes
Dermatologic paraneoplastic syndromes are generally seen before patients are diagnosed 
with cancer. It is not possible to differentiate them from their benign variants in terms of clini-
cal appearance and histopathological findings, although dermatologic PNS that suddenly 
develop at an atypical localization during the late stages of life and progress rapidly may 
indicate an accompanying malignancy and it should be investigated [7, 9, 17, 55].
2.4.1. Acanthosis nigricans
Acanthosis nigricans are characterized by skin hyperpigmentation and hyperkeratosis. It is 
most frequently seen on skin folds such as the axilla, neck, and groins. It usually accompanies 
lung adenocarcinoma.
The pathogenesis of acanthosis nigricans has not been clarified yet, although one possible 
etiology is the interactions between increased levels of insulin with insulin-like growth factor 
receptors and their effect on keratinocytes and dermal fibroblasts [56].
Malignant acanthosis nigricans regresses with the treatment of underlying malignancies, and 
isotretinoin may be preferred in cases that fail to recover [57].
2.4.2. Polymyositis/dermatomyositis
Polymyositis/dermatomyositis (PM/DM) is a disease characterized by specific skin find-
ings (skin rashes and heliotropic appearance) and inflammatory myopathy accompanying 
with proximal muscle weakness. Violet-colored edema in periorbital tissues and the eyelids 
(heliotrophy), periungual telangiectasia, dystrophic changes in the cuticula and macular, 
violet-colored erythema on the forehead, neck, upper trunk, back, deltoid region, and dorsum 
of the hand are specific findings of PM/DM [58].
In 15–30% cases of PM/DM, an underlying malignancy is the cause of PNS. Ovarian and 
breast cancer in women and lung cancer in men are the most common malignancies associ-
ated with dermatomyositis [59].
Up to 30% of patients with PM/DM have auto-antibodies against cytoplasmic and nuclear 
antigens [60].
The treatment of the underlying malignancies can help in the resolution of the findings. 
Glucocorticoids are the most important medication for the PM/DM treatment, and immuno-
suppressive agents (azathioprine, cyclophosphamide, etc.) can also be beneficial [44].
LC patients with PM/DM have poor prognosis [61].
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2.4.3. Erythema gyratum repens
Erythema gyratum repens (EGR) refers to multiple, erythematosus, serpiginous, concentric-
shaped lesions that can grow by almost 1 cm/day [62, 63], but no face, hand or foot involve-
ment is observed.
Rather than benign pathological diseases, EGR generally appears in the presence of malignant 
diseases and a carcinoma can be detected in more than 80% of patients with EGR. The most 
common type of malignancy associated with EGR is a SCLC [7, 18].
The pathogenesis of the disease is unknown and its treatment is based primarily on the iden-
tification and treatment of the underlying malignancy.
2.4.4. Erythema annulare centrifugum
Erythema annulare centrifugum (EAC) is an eruption characterized by slowly progressing, 
annular or polycyclic erythematosus lesions.
EAC, caused by benign reasons, is thought to develop due to hypersensitivity reaction. The 
pathogenesis of a figured erythema developing due to cancer, and thus EAC, is not clearly 
known, but a suggested hypothesis is that the tumor causes chemical changes in the surround-
ing tissues, inducing an antigenic status in these tissues, and these antigens lead to inflam-
mation on the skin by causing cross-reactions since they are similar to the skin proteins [63].
EAC regresses with the treatment of the underlying tumor.
2.4.5. Bazex syndrome (acrokeratosis paraneoplastica)
Bazex syndrome is characterized by hyperkeratosis of the acral regions. It appears as erythe-
matosus, papulosquamous plaques on the nose and ears, and less frequently on the finger-
nails, hands, feet, knees, and elbows. The lesions are generally likened to psoriasis [64, 65]. 
Benign forms are less frequent than malignant PNS forms.
Its mechanism of development is still unclear, however, it regresses with tumor treatment. 
Like in most PNS cases, it may appear during LC recurrence.
2.4.6. Tripe palms
It is also known as palmoplantar keratoderma, pachydermatoglyphy, or palmar hyperkera-
tosis, and is generally seen with LC and 90% of the cases are associated with neoplasm. The 
most common types of tumors are lung and gastric cancers [41].
2.4.7. Others
Other cutaneous PNS seen in LC patients include paraneoplastic pemphigus, leukocytoclastic 
vasculitis, multicentric reticulohistiocytosis, sign of leser-trelat, pruritus, and finger clubbing.
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2.5. Rheumatologic paraneoplastic syndromes
2.5.1. Hypertrophic osteoarthropathy
Hypertrophic osteoarthropathy (HO) is a syndrome characterized by finger clubbing and 
periostitis. Secondary HO, which is a PNS, is most frequently seen in LC, particularly in 
NSCLC [66]. It manifests with a clubbing of the fingers and toes, periostitis of the long bones 
and polyarthritis in some cases [67].
More than 70% of HO cases are associated with LC, and the incidence rate of HO among 
LC patients has been found to be 0.7% [41]. Periostitis is a well-known radiographic feature 
with a generally symmetric distribution, and periosteal reactions involving the long bones 
are present [67].
While theories have been suggested to explain the mechanisms of HO development, it is still 
unclear.
In addition to the cancer treatment, nonsteroidal anti-inflammatory drugs, bisphosphonates, 
and octreotide have been shown to be beneficial for the treatment of HO [41].
2.6. Hematologic paraneoplastic syndromes
Hematologic abnormalities such as anemia, leucocytosis, thrombocytosis, and eosinophilia 
are common in LC patients. However, not all of these are associated with a PNS. These condi-
tions generally follow an asymptomatic course, and coagulopathies, granulocytosis, anemia, 
and thrombocytosis can be listed among hematologic PNS [9, 68].
2.6.1. Paraneoplastic coagulopathies
Patients with LC tend to develop thrombosis. Thrombotic risk in lung cancer patients is 20-fold 
higher than in the general population. Also the risk of thrombosis development in LC is higher 
than other types of cancer. Several studies have demonstrated that the incidence of cancer 
diagnosis increases during the first 6 months following venous thromboembolism and venous 
thrombosis. There are several mechanisms of coagulopathies in patients with LC. The main 
mechanisms include thrombocytosis, activation of clotting due to injury on the vascular walls, 
increase in the level and activation of clotting factors, and production of procoagulant factor 
secondary to tumor hypoxia [18, 29, 69].
Venous thrombosis and hypercoagulability are known as Trousseau syndrome, and while 
these are mobile in character, long-term anticoagulant treatment should be considered when 
they are detected.
2.6.2. Paraneoplastic granulocytosis
Granulocytosis, in the absence of infection or leukemia, is relatively common at the time of 
diagnosis or during the follow-up of patients with LC, and it is seen in 14.5% of patients with 
LC, and the majority of which are giant-cell lung carcinoma cases [2, 68, 70].
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Granulocytosis develops due to the production of paraneoplastic hematopoietic growth fac-
tors and certain cytokines (IL-6) [70].
No specific treatment is required other than cancer treatment.
2.6.3. Paraneoplastic anemia
Anemia is seen in several types of cancer. It occurs as a PNS in cancer patients and is a normo-
cytic normochromic anemia. This condition presents with low serum iron levels, normal or 
elevated ferritin level, normal iron stores, and low serum erythropoietin levels [2].
In LC, anemia as a PNS may also develop depending on autoimmunity, known as autoim-
mune hemolytic anemia, although antibodies with a specific association are unknown [71].
Anemia generally recovers after the cancer treatment, but patients may be given an erythro-
cyte suspension in cases of severe anemia.
2.6.4. Paraneoplastic thrombocytosis
Thrombocytosis frequency is 13–32% in LC patients. IL-6 is the cytokine that is known to play a 
role in the development of paraneoplastic thrombocytosis [41]. It requires no specific treatment.
2.7. Nephrological paraneoplastic syndromes
Nephrological PNS involves a group of disorders that develop as a result of glomerulopathy, 
which may cause electrolyte imbalance and urea-creatinine elevation, leading eventually to 
renal failure.
2.7.1. Membranous nephropathy
Membranous nephropathy, developing as a PNS, is most commonly seen in patients with LC, 
and primarily in patients with NSCLC [72]. Proteinuria leads to the development of hypo-
proteinemia, resulting in edema in different parts of the body, and acute renal failure and 
hypertension may also develop in nephrotic syndrome.
The pathophysiology of membranous nephropathy involves the immune response given by 
tumor-related antigens, and antigen deposits in renal glomeruli have been reported in some 
patients [25, 73].
2.7.2. Others
Paraneoplastic glomerulopathies seen in LC patients include minimal change disease, IgA 
nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephri-
tis, crescentic glomerulonephritis, and thrombotic microangiopathies [73].
Effective cancer treatment will be sufficient when paraneoplastic glomerulopathies including 
membranous nephropathy are detected. However, renal functions should still be monitored 
and appropriately managed [74].
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2.8. Ophthalmologic paraneoplastic syndromes
Ophthalmologic PNS related to the retina or optic nerves can be seen in LC cases, and par-
ticularly in SCLC, and retinopathy and optic neuropathy may develop and result in visual 
dysfunctions. Paraneoplastic syndrome in these cases is caused by the development of 
immune reaction. The antigens associated with paraneoplastic retinopathy are recoverin and 
alpha-enolase, whereas collapsin response mediator protein 5 is the antigen associated with 
paraneoplastic optic neuropathy [75].
Treatment is based primarily on immunosuppressive therapies. However, visual functions 
may not improve despite immunosuppressive therapy and effective treatment of underlying 
cancer [76].
2.9. Others
2.9.1. Cachexia
Cachexia is frequently seen in LC patients, and develops as a result of a rather complex pro-
cess. Roughly, cachexia develops due to the chronic course of systemic inflammation associ-
ated with anorexia as well as the loss of muscle and fat mass in cancer patients [77]. While 
there is no specific treatment for cachexia, the most appropriate approach is to focus on cancer 
treatment and to provide nutritional support.
2.9.2. Fever
The diagnosis of fever as a PNS is difficult. Several conditions may cause fever in LC patients, 
including infections (bacterial, viral, parasitic, etc.), drug-induced fever, and autoimmune 
conditions other than cancer (rheumatoid arthritis, vasculitis, etc.). While the etiology of para-
neoplastic fever is not completely understood, it is believed to be mediated by cytokines [78].
In addition to LC treatment, antipyretic medications can be preferred for the treatment.
3. Conclusion
Over the last century, there has been a great deal of progress in the diagnosis and pathogen-
esis of PNS. PNS is more common in LC patients and its frequency is higher in SCLC than in 
other types of LC.
PNS may involve almost all systems and may appear before or after the diagnosis of cancer. 
The diagnosis of the lesions that appear before LC diagnosis can significantly affect the out-
comes by allowing the early identification of LC and changing its prognosis through timely 
treatment. Similarly, recurrences and remissions of PNS provide important clues during can-
cer follow-up.
A clear understanding of the mechanisms leading to PNS development in LC patients and 
improvements in the diagnostic and treatment methods will significantly provide positive 
improvements in the cancer treatment.
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